Next Article in Journal
Computed Tomography Versus Pathologic Tumor Size in Resected Lung Tumors: High Correlation, Limited Agreement, and the Impact of Ground-Glass Opacity
Next Article in Special Issue
Tensor-Valued Diffusion MRI for Microstructural Assessment During Stereotactic Radiotherapy of Brain Metastases: A Feasibility Study
Previous Article in Journal
Quantitative Consistency of Amide Proton Transfer-Weighted MRI for Brain Tumor Differentiation: Systematic Review of Clinical Evidence
Previous Article in Special Issue
Applications of Advanced Imaging for Radiotherapy Planning and Response Assessment in the Central Nervous System
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Fluoroscopy-Guided Motion Management in Particle Therapy: Evolution, Challenges, and AI-Enabled Opportunities

Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
*
Author to whom correspondence should be addressed.
Tomography 2026, 12(5), 66; https://doi.org/10.3390/tomography12050066 (registering DOI)
Submission received: 13 March 2026 / Revised: 30 April 2026 / Accepted: 1 May 2026 / Published: 9 May 2026
(This article belongs to the Special Issue Progress in the Use of Advanced Imaging for Radiation Oncology)

Simple Summary

Particle therapy delivers radiation that stops sharply at a chosen depth, sparing healthy tissue near the tumor. This precision can be undermined when the target moves during respiration, as in many lung, liver, and pancreatic tumors, where small displacements can cause underdosing of the tumor or unintended dose to adjacent organs. Fluoroscopy enables real-time imaging of the target during treatment and is therefore a promising imaging modality for motion-managed particle therapy. This review traces the evolution of fluoroscopy hardware from image intensifiers to modern flat-panel detectors integrated with proton therapy units, summarizes vendor-supported fluoroscopy-guided systems, and examines why reliable tracking still relies on implanted fiducial markers. We then survey emerging AI-based methods that could lead to marker-less tumor tracking using on-treatment fluoroscopy. Technical and clinical challenges are discussed.

Abstract

The sharp dose gradients that underpin the dosimetric advantage of particle therapy over photon therapy can be undermined by the interplay effects due to intra-fraction motion in modern pencil beam scanning systems. Fluoroscopy-Guided Particle Therapy (FGPT) offers a promising path to improved motion management through real-time tracking of tumors or surrogate signals. The advent of flat-panel detector (FPD)-based technology has enabled tighter integration of fluoroscopy/fluorography into treatment units and accelerated clinical adoption and research, with commercial systems such as Hitachi’s Real-time Gated Particle Therapy (RGPT) now available. However, the need for implanted fiducial markers, with the associated invasiveness and risk of complications, limits the utility of RGPT to a few anatomic sites in selected patients. The full potential of FGPT, therefore, depends on reliable marker-less tumor tracking, which remains challenging because soft-tissue targets are obscured by overlapping anatomy along the X-ray path, leading to reduced reliability of traditional image-registration algorithms in the projection domain. Recent advances in deep learning and AI-driven image registration have renewed hope for overcoming these barriers, enabling real-time marker-less tracking for particle therapy. This review outlines the evolution of fluoroscopy technology from image intensifier (II) to FPD-based systems, summarizes historical and recent vendor-supported FGPT strategies, and surveys emerging AI-based algorithms in the literature. A general review of machine learning-based image registration is provided, challenges in generalizability and interpretability are highlighted, and potential paths toward reliable, clinically deployable FGPT are discussed.
Keywords: fluoroscopy; particle therapy; machine learning fluoroscopy; particle therapy; machine learning

Share and Cite

MDPI and ACS Style

Li, F.; Furutani, K.M.; Beltran, C.J. Fluoroscopy-Guided Motion Management in Particle Therapy: Evolution, Challenges, and AI-Enabled Opportunities. Tomography 2026, 12, 66. https://doi.org/10.3390/tomography12050066

AMA Style

Li F, Furutani KM, Beltran CJ. Fluoroscopy-Guided Motion Management in Particle Therapy: Evolution, Challenges, and AI-Enabled Opportunities. Tomography. 2026; 12(5):66. https://doi.org/10.3390/tomography12050066

Chicago/Turabian Style

Li, Feifei, Keith M. Furutani, and Chris J. Beltran. 2026. "Fluoroscopy-Guided Motion Management in Particle Therapy: Evolution, Challenges, and AI-Enabled Opportunities" Tomography 12, no. 5: 66. https://doi.org/10.3390/tomography12050066

APA Style

Li, F., Furutani, K. M., & Beltran, C. J. (2026). Fluoroscopy-Guided Motion Management in Particle Therapy: Evolution, Challenges, and AI-Enabled Opportunities. Tomography, 12(5), 66. https://doi.org/10.3390/tomography12050066

Article Metrics

Back to TopTop